Why treat mHSPC early with ERLEADA®?
Early treatment decisions are key to pushing back on disease progression[1]
Treating mHSPC patients early with ERLEADA® + ADT is associated with a lower frequency of AR aberrations relative to placebo + ADT[4][5]
The TITAN final analysis emphasises the benefit of early, potent, AR-signalling inhibition with ERLEADA® at the time of initial ADT for mHSPC and before progression to mCRPC.[1]
- Patients with AR aberrations at the end of treatment had worse outcomes vs. patients without[4]
- ERLEADA® + ADT was associated with decreased frequency of AR aberrations at the end of treatment vs. placebo + ADT[4][5]
Taken together, these findings suggest that early ERLEADA® + ADT provides long-term benefits vs. placebo + ADT without increased development of AR aberrations.[4]
aIn a Phase III study including patients with mHSPC on placebo + ADT.[1]
In mHSPC, early treatment decisions are key to pushing back on disease progression[1]
What if you could delay your patients’ progression to castration resistance and extend their lives?
Abbreviations
ADT, androgen deprivation therapy. AR, androgen receptor. EAU, European Association of Urology. M1, metastasised outside the pelvis. mCRPC, metastatic castration-resistant prostate cancer. mHSPC, metastatic hormone-sensitive prostate cancer. QoL, quality of life.
Titular da Autorização de Introdução no Mercado: Janssen-Cilag International NV, Turnhoutseweg 30, B-2340 Beerse, Bélgica.
Para mais informações deverá contactar o Representante do Titular da Autorização de Introdução no Mercado: Janssen-Cilag Farmacêutica, Lda.
Medicamento de receita médica restrita, de utilização reservada a certos meios especializados.
Antes de prescrever consulte o RCM completo.
RCM de Erleada®, veja aqui
